



## COMMUNICATION PENSTAPHO®

Paris, December 15, 2020

Madam, Sir,

Laboratoires DELBERT acquired marketing authorizations for the product PENSTAPHO® in January 2019 with the intention of ensuring the commercial return of this injectable antibiotic.

PENSTAPHO® has undergone full pharmaceutical development using new manufacturing companies in Europe for the finished product.

**PENSTAPHO® 1g/5ml Polvere e solvente per soluzione iniettabile**

**Therefore, PENSTAPHO will be available following distributor:**

ALLOGA ITALIA sito in PADOVA

Line 1: Corso Stati Uniti 9a

I-35020 PADOVA

[alloga.ordini@alloga.it](mailto:alloga.ordini@alloga.it)

[+39 049 870 0344](tel:+390498700344)

DELBERT LABORATORIES are committed to meeting the needs of patients and healthcare professionals and are now able to market PENSTAPHO **without disruption** irrespective of the channel.

For any medical inquiries, complaints or pharmacovigilance issue, please contact our local representative:

DI RENZO

Viale Manzoni 59

00185 Roma

[pharmacovigilance@direnzo.biz](mailto:pharmacovigilance@direnzo.biz)

[+39 06 77 20 90 20](tel:+390677209020)

With best regards,

Thierry Hoffmann

General Manager

Laboratoires Delbert Sas

3 Villa Poirier

75015 Paris

France